Submission of outcome and proceedings of 31st Annual General Meeting of the Company held today i.e on 29.09.2025
Awaiting price reaction for this filing.
MPS Pharmaa Ltd (formerly Advik Laboratories Ltd) held its 31st Annual General Meeting on 29 September 2025, chaired by Managing Director Mr. Peeyush Kumar Aggarwal. Four ordinary resolutions were transacted: adoption of audited financial statements for FY ended 31 March 2025 (which includes a profit and loss account, indicating the company reported a loss for the year), reappointment of Mr. Peeyush Kumar Aggarwal as director liable to retire by rotation, approval for related party transactions under Section 188 of the Companies Act, 2013, and appointment of a secretarial auditor. Voting was conducted through remote e-voting (closed 28 September) and physical ballot at the meeting, with Mr. Kundan Agarwal appointed as scrutinizer. The meeting concluded at 10:05 AM and combined voting results are to be filed with BSE, ASE, and the Registrar of Companies within two working days.
This is a routine compliance filing confirming that standard AGM business items were conducted smoothly. Shareholders should await the voting results (to be filed within 2 working days) to see approval margins, especially on the related party transactions which directly affect specific shareholders' interests. The company also reportedly had losses in FY25, which contextualises the financial statements adoption.